Physician profile
Muhammad Hyder
NPI 1013085257
$1,712.73
in general payments reported to CMS, 2019-2025
11 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Addiction Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $102 · 2021: $325 · 2022: $72.98 · 2023: $318 · 2024: $431 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,079.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $785.62 | 2022-2025 | Caplyta |
| Abbvie INC. | $346.50 | 2021-2024 | |
| Almatica Pharma LLC | $149.61 | 2021-2024 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $101.61 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $93.94 | 2019-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $77.85 | 2019-2020 | |
| Allergan, INC. | $55.10 | 2020 | |
| Neuronetics, INC. | $37.89 | 2019 | |
| Avanir Pharmaceuticals, INC. | $36.39 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Hyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.